TRexBio

TRexBio

Edit info

  • Founded: 2018
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Immune-mediated disease
  • Drug types: IMM
  • Lead product: TRB-051
  • Funding: $26M A Mar 2022; $57M A Jun 2021


trex.bio

linkedin.com

job board


Drug notes:

5 additional programs RD immune-mediated disease

About:

TRexBio is developing technology for functional manipulation of immune cells. The immune system plays a significant role in the development of disease. This includes regulatory T cells (Tregs) that mediate tissue healing. Using their Deep Biology platform, TRexBio is mapping Treg behavior in human tissue to dysregulation in disease. This enables TRexBio to identify novel therapeutics for the treatment of immune-mediated diseases. Currently, TRexBio is advancing multiple large molecule therapeutic candidates with their lead program, TRB-051 in clinical stages.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com